Acquisitions and License Agreements (Narrative) (Details) - USD ($) $ in Millions								3 Months Ended										12 Months Ended				60 Months Ended
	Dec. 11, 2017	Oct. 02, 2017	Sep. 25, 2017	Aug. 31, 2016	Feb. 01, 2016	Sep. 25, 2015	Apr. 16, 2015	Mar. 30, 2018	Dec. 29, 2017	Sep. 29, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 30, 2016	Sep. 30, 2016	Jun. 24, 2016	Mar. 25, 2016	Dec. 25, 2015	Dec. 29, 2017	Sep. 30, 2016	Sep. 25, 2015	Sep. 26, 2014	Sep. 27, 2013	Jan. 06, 2017	Aug. 31, 2014
Business Acquisition [Line Items]
Payments to Acquire Businesses, Net of Cash Acquired													$ 1.8				$ 0.0	$ 76.3	$ 245.4	$ 2,154.7
Cash used to acquire business				$ 0.0	$ 0.0	$ 0.0	$ 0.0
Net sales									$ 792.3	$ 793.9	$ 824.5	$ 810.9	829.9	$ 887.2	$ 866.6	$ 815.8	811.2	3,221.6	3,380.8	2,923.1
Non-cash impairment charges													214.3				$ 0.0	63.7	16.9	0.0
Ocera [Member]
Business Acquisition [Line Items]
Contingent consideration	$ 22.0
Business Combination, Consideration Transferred, Other	42.4
Total consideration	64.4
Cash used to acquire business								$ (1.9)
Total Debt	0.0
Contingent consideration, potential maximum	$ 75.0
Net sales													0.0					0.0	0.0	0.0
InfaCare [Member]
Business Acquisition [Line Items]
Contingent consideration			$ 35.0
Business Combination, Consideration Transferred, Other			80.4
Total consideration			73.1
Cash used to acquire business			0.0
Total Debt			30.0
Contingent consideration, potential maximum			345.0
Business Combination, Cash Paid for Consideration			37.2
Other liabilities (non-current)			$ 43.2
Net sales													0.0					0.0	0.0	0.0
Stratatech [Member]
Business Acquisition [Line Items]
Contingent consideration				54.9
Business Combination, Consideration Transferred, Other				76.0
Total consideration				130.9
Total Debt				1.0
Contingent consideration, potential maximum				$ 121.0
Hemostasis Products
Business Acquisition [Line Items]
Contingent consideration					52.0
Business Combination, Consideration Transferred, Other					173.5
Total consideration					225.5
Total Debt					0.0
Contingent consideration, potential maximum					$ 395.0
Therakos
Business Acquisition [Line Items]
Contingent consideration						0.0														0.0
Business Combination, Consideration Transferred, Other						1,300.0
Total consideration						1,019.1
Cash used to acquire business						(1,000.0)
Total Debt						344.8														344.8
Net sales													47.4					214.9	207.6	0.0
Ikaria
Business Acquisition [Line Items]
Contingent consideration							0.0
Business Combination, Consideration Transferred, Other							2,300.0
Total consideration							1,253.6
Cash used to acquire business							(1,200.0)
Total Debt							1,121.0
Long Term Debt Assumed							1,100.0
Net sales													121.4					515.1	491.5	191.9
NeuroproteXeon [Member]
Business Acquisition [Line Items]
Business Combination, Consideration Transferred, Other		$ 10.0
Business Combination, Contingent Consideration, Potential Payment		$ 25.0
Mesoblast [Member]
Business Acquisition [Line Items]
Payments to Acquire Marketable Securities																		21.5
Available-for-sale Securities, Current																							$ 19.7
Intangible Assets, Current																							$ 1.8
Questcor Pharmaceuticals, Inc.
Business Acquisition [Line Items]
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Contingent Liability									111.8				124.7					111.8						$ 195.4
Contingent consideration, potential maximum									$ 140.0									140.0
Raplixa [Member]
Business Acquisition [Line Items]
Impairment of Intangible Assets, Finite-lived																		63.7
Bristol-Myers Squibb | Licensing Agreements
Business Acquisition [Line Items]
Contingent payment, maximum additional amount																			25.0
Royalties paid													14.7					53.9	46.3	43.9
Ofirmev | Cadence Pharmaceuticals, Inc. | Licensing Agreements
Business Acquisition [Line Items]
Milestone Payments																				10.0
Exalgo | Licensing Agreements
Business Acquisition [Line Items]
Contingent payment, maximum additional amount																				73.0
Royalties paid													0.2					0.2	0.9	3.2
Milestone Payments																						$ 65.0
Depomed | Licensing Agreements
Business Acquisition [Line Items]
Contingent payment, maximum additional amount																			64.0
Milestone Payments																					$ 10.0	22.0
Xartemis [Member]
Business Acquisition [Line Items]
Impairment of Intangible Assets, Finite-lived													7.3
Finite-Lived Intangible Assets | Exalgo | Licensing Agreements
Business Acquisition [Line Items]
Milestone Payments																						$ 55.0
Debentures | Therakos
Business Acquisition [Line Items]
Long term debt						750.0
Debentures | Ikaria
Business Acquisition [Line Items]
Long term debt							1,400.0
Revolving Credit Facility | Therakos
Business Acquisition [Line Items]
Borrowings, outstanding						$ 500.0														500.0
Revolving Credit Facility | Ikaria
Business Acquisition [Line Items]
Borrowings, outstanding							$ 240.0
Cost of Sales
Business Acquisition [Line Items]
Amortization Of Inventory Step-Up To Cost Of Sales													$ 3.6					$ 10.1	$ 24.3	$ 44.1